Zenas BioPharma shares rise 10.85% intraday as company to present autoimmune disease therapy updates at Guggenheim 2026 Biotech Summit.

Wednesday, Feb 4, 2026 10:45 am ET1min read
ZBIO--
Zenas BioPharma surged 10.85% intraday, announcing that its management will present at the Guggenheim Emerging Outlook: 2026 Biotech Summit on February 11, 2026. The presentation will cover R&D progress in autoimmune disease therapies and will be webcast via the company's website. The firm is a clinical-stage global biopharma company focused on developing transformative therapies for autoimmune diseases, currently advancing two late-stage candidates: obexelimab and orelabrutinib.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet